Description
GLPG-0634 is a triazolopyridine that inhibits JAK1; it exhibits anti-inflammatory and immunomodulatory activities. GLPG-0634 prevents release of inflammatory cytokines and is currently under investigation as a potential treatment for rheumatoid arthritis and Crohn’s disease.